Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
Open accessThe DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. As these intracellular second messengers control many cellular homeostatic processes, dysregulation of their signals and signaling pathways initiate or modulate pathophysiological pathways related to various disease states, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication, chronic obstructive pulmonary disease, and psoriasis. Alterations in expression of PDEs and PDE‐gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. PDEs also play important role in formation and function of multimolecular signaling/regulatory complexes, called signalosomes. At specific intracellular locations, individual PDEs, together with pathway‐specific signaling molecules, regulators, and effectors, are incorporated into specific signalosomes, where they facilitate and regulate compartmentalization of cyclic nucleotide signaling pathways and specific cellular functions. Currently, only a limited number of PDE inhibitors (PDE3, PDE4, PDE5 inhibitors) are used in clinical practice. Future paths to novel drug discovery include the crystal structure‐based design approach, which has resulted in generation of more effective family‐selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lynch, M. J., Baillie, G. S., Mohamed, A., Li, X., Maisonneuve, C., Klussmann, E., van Heeke, G., & Houslay, M. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414316200 · Cited by 206 · cited 22×
“…AC Cardiac I(Ks) potassium channel and arrhythmia (Terrenoire et al, 2009) AKAP79 PDE4D, b-arrestin, b2AR, ERK, PKA b2AR activation of ERK (Lynch et al, 2005) AKAP95, AKAP149, MTG PDE4A, PDE7A, PKA-RII Activation of T-cells (Asirvatham et al, 2004) mAKAP PDE4D, PKA, RyR2 Myocardial…”
InfluentialRetractedOsteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Maintenance of normal bone mass depends on the balance between osteoblast bone formation and osteoclast bone destruction (Duong and Rodan, 2001; Boyle et al, 2003).”
BackgroundCardiac excitation–contraction coupling
Bers, D. M. (2002) · Nature · doi:10.1038/415198a · Cited by 4,744 · cited 1×
“Thus, as components of different AKAP-based signalosomes, PDE4B, PDE4D, and PDE3A regulate different phases of the calcium-mediated excitation–contraction coupling cycle and offer Oral Diseases 9 protection against arrhythmias (Bers, 2002).”
BackgroundEffect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225 · cited 1×
“Although PDE3 inhibitors were developed to improve hemodynamic responses in patients with heart failure, in clinical trials, chronic administration of the PDE3 inhibitor milrinone increased mortality, most likely due to arrhythmias and cardiac arrest (Packer et al, 1991).”
BackgroundEpac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969 · cited 1×
“…sites in addition to their catalytic sites (Bender and Beavo, 2006; Manganiello et al, 2007; Tsai and Kass, 2009; Francis et al, 2011). cAMP binding directly activates Epac proteins, resulting in activation of Rap1 (small GTPase) and diverse Rap1signaling pathways (de Rooij et al, 1998; Bos, 2006).”
BackgroundCyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781 · cited 23×
“mediate cyclic nucleotide actions, for example, Epac 1 and Epac 2 (cAMP-activated guanine-nucleotide-exchange proteins), cyclic-nucleotide-gated (CNG) ion channels, and several PDEs (especially PDEs 2, 5, 6) that contain allosteric cyclic-nucleotide-binding sites in addition to their catalytic sites (Bender and Beavo,…”
BackgroundInfluentialResveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Self-citationConti, M., & Beavo, J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.150444 · Cited by 1,183 · cited 2×
“…include two domains: NHR1 (amino acids 1–300), which contains a large hydrophobic domain with five to six predicted transmembrane helices, and NHR2 (aa 300–500), with a smaller hydrophobic region of ~50 aa (Taira et al, 1993; Degerman et al, 1997; Hambleton et al, 2005; Conti and Beavo, 2007).”
BackgroundGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
Francis, S. H., Busch, J. L., & Corbin, J. D. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002907 · Cited by 1,028 · cited 1×
“PDE1 activity is determined by intracellular Ca2+ levels (Francis et al, 2010).”
BackgroundAdvances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776 · cited 15×
“…AKAPs, and/or other scaffold proteins (Table 2 represents a partial list of PDE-containing signalosomes, with scaffold proteins, known interacting partners, and presumed function) (Houslay et al, 2007; Tsai and Kass, 2009; Keravis and Lugnier, 2010; Francis et al, 2011; Maurice et al, 2014a,b).”
BackgroundInfluentialSelf-citationHodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718 · cited 1×
“Currently, Forteo (N-terminal PTH peptide, 1-34 amino acid) is FDA-approved for anabolic treatment of osteoporosis (Hodsman et al, 2005; Canalis, 2010).”
BackgroundDiabetes mellitus : a fundamental and clinical text
LeRoith, D., Taylor, S. I., & Olefsky, J. M. (2004) · Cited by 699
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1564 · Cited by 694 · cited 1×
“Currently, in certain instances, theoplylline is used as adjunct therapy in asthma, COPD, emphysema, and chronic bronchitis, and is being evaluated in corticosteroidresistant asthma and COPD (ClinicalTrials.gov Identifier: NTC00241631) (Barnes, 2013).”
BackgroundPhosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma Agents
TORPHY, T. J. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9708012 · Cited by 657 · cited 3×
“There has been considerable effort to develop PDE4 inhibitors as therapeutics for important pulmonary inflammatory diseases, especially asthma, allergic rhinitis, COPD, and idiopathic pulmonary fibrosis (Torphy, 1998).”
BackgroundMammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639 · cited 16×
“…AKAPs, and/or other scaffold proteins (Table 2 represents a partial list of PDE-containing signalosomes, with scaffold proteins, known interacting partners, and presumed function) (Houslay et al, 2007; Tsai and Kass, 2009; Keravis and Lugnier, 2010; Francis et al, 2011; Maurice et al, 2014a,b).”
BackgroundInfluentialKeynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635 · cited 5×
“…activation (Asirvatham et al, 2004) PDE8 AKAP-LBC PDE8A, Raf1, PKA, AKAP-Lbc, MEK, ERK PDE8A binds Raf1 and exerts inhibitory effect on Raf1 and ERK signaling (Smith et al, 2010; Brown et al, 2013) Oral Diseases 6 Variants lacking both UCR1 and UCR2 are catalytically inactive (Houslay et al, 2005).”
BackgroundInfluentialSildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629 · cited 1×
“Inhibitors of PDE5 increase cGMP/PKG signaling, which results in pulmonary vasodilation and inhibition of vascular hypertrophy and pathological remodeling (Ghofrani et al, 2006).”
BackgroundFabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614 · cited 1×
“…to reduce exacerbations in subsets of COPD patients with bronchitis, and as an add-on therapy to patients receiving inhaled corticosteroids, or standard bronchodilators such as longacting b2AR agonists (LABA) or anticholinergic drugs (Fabbri et al, 2009; Rabe, 2011; Giembycz and Newton, 2014).”
BackgroundThe gene encoding phosphodiesterase 4D confers risk of ischemic stroke
Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S. T., Manolescu, A., Jonsdottir, S., Jonsdottir, T., Gudmundsdottir, T., Bjarnadottir, S. M., Einarsson, O. B., Gudjonsdottir, H. M., et al. (2003) · Nature Genetics · doi:10.1038/ng1245 · Cited by 564 · cited 1×
“Similarly, human PDE4D haplotypes and single-nucleotide polymorphisms (SNPs) have been correlated with ischemic stroke (Gretarsdottir et al, 2003) and with responses to short-acting bronchodilators in pediatric asthma (Labuda et al, 2011), whereas PDE4B SNPs and decreased expression of PDE4B are…”
BackgroundThe protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways
Dodge-Kafka, K. L., Soughayer, J., Pare, G. C., Carlisle Michel, J. J., Langeberg, L. K., Kapiloff, M. S., & Scott, J. D. (2005) · Nature · doi:10.1038/nature03966 · Cited by 556 · cited 7×
“In cardiomyocytes, an mAKAP-organized signalosome that is located at the nuclear envelope also modulates cAMP-mediated hypertrophic responses. mAKAP provides the scaffold for signalosomes that contain PDE4D3, PKA, Epac1, PP2A, adenylyl cyclase, and an ERK signaling module (Bauman et al, 2007; Dhanasekaran et al, 2007;…”
BackgroundInfluentialEpac proteins: multi-purpose cAMP targets
Bos, J. L. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.10.002 · Cited by 532 · cited 2×
“cAMP binding directly activates Epac proteins, resulting in activation of Rap1 (small GTPase) and diverse Rap1signaling pathways (de Rooij et al, 1998; Bos, 2006).”
BackgroundBehavioral phenotypes of Disc1 missense mutations in mice
Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.015 · Cited by 526 · cited 1×
“In addition, DISC1 (disrupted in schizophrenia homolog 1), a known risk factor for schizophrenia, and PDE4B interact physically in cells to influence the catalytic activity of PDE4B (Table 2) (Clapcote et al, 2007; Millar et al, 2007).”
BackgroundLehnart, S. E., Wehrens, X. H. T., Reiken, S., Warrier, S., Belevych, A. E., Harvey, R. D., Richter, W., Jin, S.-L. C., Conti, M., & Marks, A. R. (2005) · Cell · doi:10.1016/j.cell.2005.07.030 · Cited by 517 · cited 14×
“…cardiomyopathy, with dysregulation of Ca2+ transients and increased incidence of arrhythmias, associated with cAMP/PKA-induced hyperphosphorylation of the RyR2, which was likely due to the absence of PDE4D3 from a signalosome containing a mAKAP/PKA/PDE4D/RyR2 complex (Lehnart et al, 2005).”
BackgroundInfluentialCyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte
Norris, R. P., Ratzan, W. J., Freudzon, M., Mehlmann, L. M., Krall, J., Movsesian, M. A., Wang, H., Ke, H., Nikolaev, V. O., & Jaffe, L. A. (2009) · Development · doi:10.1242/dev.035238 · Cited by 516 · cited 1×
“For example, PDE3 inhibitors, not PDE4 or 5 inhibitors, inhibit oocyte maturation in cultured mammalian oocytes, and administration of PDE3 inhibitors blocked pregnancy in intact rodents (Wiersma et al, 1998; Masciarelli et al, 2004; Norris et al, 2009).”
BackgroundmAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
Dodge, K. L. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1921 · Cited by 507 · cited 3×
“…and diversity of compartmentalized cyclic nucleotide signaling and allows integration and cross talk between cyclic nucleotide signals and other signaling networks and systems (Dodge et al, 2001; Houslay et al, 2007; Dodge-Kafka et al, 2010; Stangherlin et al, 2011; Kritzer et al, 2012).”
BackgroundA genetically encoded, fluorescent indicator for cyclic AMP in living cells
Zaccolo, M., De Giorgi, F., Cho, C. Y., Feng, L., Knapp, T., Negulescu, P. A., Taylor, S. S., Tsien, R. Y., & Pozzan, T. (2000) · Nature Cell Biology · doi:10.1038/71345 · Cited by 485 · cited 1×
“…or biosensors, such as Epac-based cAMP sensors and cyclic nucleotide-sensitive ion channels, have verified the temporal, spatial, and functional compartmentalization of cyclic nucleotides and their signaling pathways (Jurevicius and Fischmeister, 1996; Zaccolo et al, 2000; Francis et al, 2011).”
BackgroundPatrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.017 · Cited by 468
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
Barad, M., Bourtchouladze, R., Winder, D. G., Golan, H., & Kandel, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15020 · Cited by 431
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown
Houslay, M. D. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.09.007 · Cited by 430 · cited 3×
“PDEs are not only critical regulators of the amplitude, duration, and termination of intracellular cyclic nucleotide signals, but PDEs also play an important role in this exquisite compartmentalization (Houslay, 2010; Conti et al, 2014; Maurice et al, 2014a).”
BackgroundStructure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)
Degerman, E., Belfrage, P., & Manganiello, V. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.6823 · Cited by 428 · cited 2×
“…include two domains: NHR1 (amino acids 1–300), which contains a large hydrophobic domain with five to six predicted transmembrane helices, and NHR2 (aa 300–500), with a smaller hydrophobic region of ~50 aa (Taira et al, 1993; Degerman et al, 1997; Hambleton et al, 2005; Conti and Beavo, 2007).”
BackgroundSelf-citationCyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Tsai, E. J., & Kass, D. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.009 · Cited by 420 · cited 14×
“…AKAPs, and/or other scaffold proteins (Table 2 represents a partial list of PDE-containing signalosomes, with scaffold proteins, known interacting partners, and presumed function) (Houslay et al, 2007; Tsai and Kass, 2009; Keravis and Lugnier, 2010; Francis et al, 2011; Maurice et al, 2014a,b).”
BackgroundInfluentialBurgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 397 · cited 5×
“The structure-based design approach was recently used to develop potent and family-selective PDE4 (Card et al, 2005; Burgin et al, 2010), PDE9A (Claffey et al, 2012; Meng et al, 2012), and PDE10A (Malamas et al, 2011; Ho et al, 2012) inhibitors.”
BackgroundMethodInfluentialKeravis, T., & Lugnier, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01729.x · Cited by 385 · cited 6×
“The signalosome concept has also been a crucial driving force in the development of novel approaches to targeting individual PDEs Oral Diseases 15 (Houslay, 2010; Keravis and Lugnier, 2012; Lee et al, 2013a; Maurice et al, 2014a).”
BackgroundInfluentialJurevicius, J., & Fischmeister, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.295 · Cited by 373 · cited 1×
“…or biosensors, such as Epac-based cAMP sensors and cyclic nucleotide-sensitive ion channels, have verified the temporal, spatial, and functional compartmentalization of cyclic nucleotides and their signaling pathways (Jurevicius and Fischmeister, 1996; Zaccolo et al, 2000; Francis et al, 2011).”
BackgroundJin, S.-L. C., & Conti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122041599 · Cited by 367 · cited 1×
“Many studies, especially those with PDE4 KO mice, have demonstrated that individual PDE4 subtypes play complementary, not redundant, roles in the control of cell functions (Hansen et al, 2000; Jin and Conti, 2002; Ariga et al, 2004; Jin et al, 2006; Peter et al, 2007; Beca et al, 2011).”
BackgroundNikolaev, V. O., Bünemann, M., Schmitteckert, E., Lohse, M. J., & Engelhardt, S. (2006) · Circulation Research · doi:10.1161/01.res.0000250046.69918.d5 · Cited by 346 · cited 2×
“…responses by increasing a discrete pool of cAMP, which is regulated by PDE4 isoforms and which activates and phosphorylates key regulators of the excitation/contraction cycle, whereas b2AR-mediated signals are regulated by multiple PDEs, including PDE3, PDE3, and PDE4 (Nikolaev et al, 2006).”
BackgroundBoess, F. G., Hendrix, M., van der Staay, F.-J., Erb, C., Schreiber, R., van Staveren, W., de Vente, J., Prickaerts, J., Blokland, A., & Koenig, G. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.040 · Cited by 330
Houslay, M. D., Baillie, G. S., & Maurice, D. H. (2007) · Circulation Research · doi:10.1161/01.res.0000261934.56938.38 · Cited by 317
Self-citationSelective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
Lugnier, C., Schoeffter, P., Le Bec, A., Strouthou, E., & Stoclet, J. C. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90333-3 · Cited by 301 · cited 1×
“…as well as different sensitivities to available inhibitors and effectors such as calcium/calmodulin), identified five distinct PDEs, now recognized as PDEs1–5 (Thompson and Appleman, 1971; Thompson et al, 1979; Keravis et al, 1980; Yamamoto et al, 1983; Weishaar et al, 1985; Lugnier et al, 1986).”
BackgroundPTH and PTHrP signaling in osteoblasts
Datta, N. S., & Abou-Samra, A. B. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.012 · Cited by 295 · cited 2×
“PTH and its active N-terminal peptide, which acts through PTH receptor 1 (PTHR1), signal via cAMP/PKA and Ca2+/PKC pathways (Aghaloo et al, 2006; Datta and Abou-Samra, 2009; Nakao et al, 2009).”
BackgroundCyclic Nucleotide-Gated Channels
Biel, M., & Michalakis, S. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68964-5_7 · Cited by 288
Scaffold proteins of MAP-kinase modules
Dhanasekaran, D. N., Kashef, K., Lee, C. M., Xu, H., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210411 · Cited by 288 · cited 1×
“…at the nuclear envelope also modulates cAMP-mediated hypertrophic responses. mAKAP provides the scaffold for signalosomes that contain PDE4D3, PKA, Epac1, PP2A, adenylyl cyclase, and an ERK signaling module (Bauman et al, 2007; Dhanasekaran et al, 2007; Houslay et al, 2007; Kritzer et al, 2012).”
BackgroundThe two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding
Martinez, S. E., Wu, A. Y., Glavas, N. A., Tang, X.-B., Turley, S., Hol, W. G. J., & Beavo, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192374899 · Cited by 286 · cited 1×
“Crystal structure of the PDE2A regulatory region indicated that its GAF-A domain is involved in dimerization and its GAF-B domain in cGMP binding (Martinez et al, 2002).”
BackgroundSiuciak, J. A., Chapin, D. S., Harms, J. F., Lebel, L. A., McCarthy, S. A., Chambers, L., Shrikhande, A., Wong, S., Menniti, F. S., & Schmidt, C. J. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.013 · Cited by 278 · cited 1×
“Phosphodiesterase 10A (PDE10A), which hydrolyzes both Oral Diseases 11 cAMP and cGMP with high affinity, is relatively highly expressed in dopaminoreceptive medium spiny neurons of the striatum and regulates cyclic nucleotide activation of these neurons (Siuciak et al, 2006).”
BackgroundRabe, K. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01218.x · Cited by 273 · cited 5×
“…to reduce exacerbations in subsets of COPD patients with bronchitis, and as an add-on therapy to patients receiving inhaled corticosteroids, or standard bronchodilators such as longacting b2AR agonists (LABA) or anticholinergic drugs (Fabbri et al, 2009; Rabe, 2011; Giembycz and Newton, 2014).”
BackgroundInfluentialRobichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267 · cited 4×
“Multiple studies, especially those with PDE4 KO mice, have pointed to inhibition of PDE4D and not other PDE4 isoforms as most likely responsible for the emetic effects (Robichaud et al, 2002) as well as the antidepressant and pro-cognitive and memory-enhancing responses to pan-PDE4 inhibitors.”
BackgroundInfluentialSelective phosphodiesterase inhibitors: a promising target for cognition enhancement
Reneerkens, O. A. H., Rutten, K., Steinbusch, H. W. M., Blokland, A., & Prickaerts, J. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1273-x · Cited by 266
Rho-A Is Critical for Osteoclast Podosome Organization, Motility, and Bone Resorption
Chellaiah, M. A., Soga, N., Swanson, S., McAllister, S., Alvarez, U., Wang, D., Dowdy, S. F., & Hruska, K. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.11993 · Cited by 263 · cited 1×
“In osteoclasts, Rho-A, which is critical for osteoclast motility and function, can be directly phosphorylated and inactivated by PKA (Chellaiah et al, 2000, 2003; Nakamura et al, 2007).”
BackgroundCyclic nucleotide phosphodiesterase 3A–deficient mice as a model of female infertility
Masciarelli, S., Horner, K., Liu, C., Park, S. H., Hinckley, M. D., Hockman, S. C., Nedachi, T., Jin, C., Conti, M., & Manganiello, V. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421804 · Cited by 261
Self-citationYuan, J., Zhang, R., Yang, Z., Lee, J., Liu, Y., Tian, J., Qin, X., Ren, Z., Ding, H., Chen, Q., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.012 · Cited by 260
Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215506 · Cited by 259
Huang, S. H., Pittler, S. J., Huang, X., Oliveira, L., Berson, E. L., & Dryja, T. P. (1995) · Nature Genetics · doi:10.1038/ng1295-468 · Cited by 253 · cited 1×
“Mutations in human PDE6a, b, or c subunits are associated with hereditary eye diseases, including night blindness and retinitis pigmentosa (Gal et al, 1994; Huang et al, 1995).”
BackgroundBeyond Counting Photons: Trials and Trends in Vertebrate Visual Transduction
Burns, M. E., & Arshavsky, V. Y. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.014 · Cited by 250 · cited 2×
“In retinal rods and cones, light-induced activation of photoreceptor PDE6 results in hydrolysis of cGMP, alterations in Ca++ current, and initiation of visual signal transduction (Burns and Arshavsky, 2005).”
BackgroundWeishaar, R. E., Cain, M. H., & Bristol, J. A. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm50001a001 · Cited by 248 · cited 1×
“…as well as different sensitivities to available inhibitors and effectors such as calcium/calmodulin), identified five distinct PDEs, now recognized as PDEs1–5 (Thompson and Appleman, 1971; Thompson et al, 1979; Keravis et al, 1980; Yamamoto et al, 1983; Weishaar et al, 1985; Lugnier et al, 1986).”
BackgroundGal, A., Orth, U., Baehr, W., Schwinger, E., & Rosenberg, T. (1994) · Nature Genetics · doi:10.1038/ng0594-64 · Cited by 246
Thompson, W. J., Terasaki, W. L., Epstein, P. M., & Sj, S. (1979) · PubMed · Cited by 242
An Effect of Insulin on Cyclic Adenosine 3′:5′-Monophosphate Phosphodiesterase Activity in Fat Cells
Manganiello, V., & Vaughan, M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43374-7 · Cited by 242 · cited 1×
“With respect to PDE localization/compartmentalization, early studies indicated that in rat adipocytes, insulin-induced activation of a membrane-associated PDE3, not cytosolic PDEs, was critical in its antilipolytic action (Manganiello and Vaughan, 1973; Elks and Manganiello, 1985).”
BackgroundSelf-citationVinpocetine inhibits NF-κB–dependent inflammation via an IKK-dependent but PDE-independent mechanism
Jeon, K.-I., Xu, X., Aizawa, T., Lim, J. H., Jono, H., Kwon, D.-S., Abe, J.-I., Berk, B. C., Li, J.-D., & Yan, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914414107 · Cited by 241
Hayes, J. S., Brunton, L. L., & Mayer, S. E. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70757-1 · Cited by 241 · cited 1×
“Early studies, for example, indicated that in perfused rat hearts, although both epinephrine and PGE1 increased cAMP and PKA activity, they activated different pools of PKA, with only epinephrine increasing phosphorylase activity and myocardial contractility (Hayes et al, 1980).”
BackgroundWachtel, H. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90239-3 · Cited by 240 · cited 1×
“PDE4 inhibitors, which were initially observed to exhibit antidepressant actions in humans (Wachtel, 1983), improve cognition and long-term memory in healthy rodents as well as rodent models of human genetic diseases (Richter et al, 2013).”
BackgroundMacKenzie, S. J., Baillie, G. S., McPhee, I., Bolger, G. B., & Houslay, M. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16609 · Cited by 238 · cited 9×
“One such PDE4Dselective allosteric inhibitor, D159687, was developed and shown to have potent anti-inflammatory effects in celland animal models and also to improve memory and cognition in mice, with minimal emesis side effects, C-terminal domain Conserved catalytic domain Regulatory domain Targeting domain ● PDE sign…”
BackgroundInfluentialGene expression in osteoblastic cells.
Rodan, G. A., & Noda, M. (1991) · PubMed · Cited by 229
Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
Archer, S. L., & Michelakis, E. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmct0904473 · Cited by 224 · cited 1×
“PDE5 inhibitor formulations for pulmonary hypertension, that is, sildenafil (Revatio), tadalafil (Adcirca), and vardenafil, are FDA-approved as part of the therapeutic armamentarium for pulmonary hypertension (Archer and Michelakis, 2009).”
BackgroundInvolvement of αvβ3 integrins in osteoclast function
Nakamura, I., Duong, L. T., Rodan, S. B., & Rodan, G. A. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0773-9 · Cited by 224
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
Bischoff, E. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901208 · Cited by 223 · cited 1×
“Sildenafil, which is highly selective for PDE5, also inhibits PDE1 with 40-fold less selectivity (Bischoff, 2004).”
BackgroundShailubhai, K., Yu, H., Karunanandaa, K., Wang, J. Y., Eber, S. L., Wang, Y., Joo, N. S., Kim, H. D., Miedema, B. W., Abbas, S. Z., et al. (2000) · PubMed · Cited by 219
Verde, I., Pahlke, G., Salanova, M., Zhang, G., Wang, S., Coletti, D., Onuffer, J., Jin, S.-L. C., & Conti, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006546200 · Cited by 217 · cited 2×
“2, PLB Arrhythmia (Ghigo et al, 2012) PI3K PKB, PDE4 Activation of T-cells (Bjorgo et al, 2010) RACK-1, b-arrestin PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal devel…”
BackgroundCard, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P. N., Artis, D. R., Bollag, G., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1059 · Cited by 208 · cited 1×
“The structure-based design approach was recently used to develop potent and family-selective PDE4 (Card et al, 2005; Burgin et al, 2010), PDE9A (Claffey et al, 2012; Meng et al, 2012), and PDE10A (Malamas et al, 2011; Ho et al, 2012) inhibitors.”
MethodAKAP complex regulates Ca 2+ re‐uptake into heart sarcoplasmic reticulum
Lygren, B., Carlson, C. R., Santamaria, K., Lissandron, V., McSorley, T., Litzenberg, J., Lorenz, D., Wiesner, B., Rosenthal, W., Zaccolo, M., et al. (2007) · EMBO reports · doi:10.1038/sj.embor.7401081 · Cited by 202 · cited 1×
“…proteins, was reported to regulate cAMP/PKA phosphorylation of phospholamban and subsequent activation of SERCA2 and uptake of Ca2+ during diastole (Lygren et al, 2007; Beca et al, 2013); a similar AKAP-based signalosome, containing human PDE3A, appears to regulate SERCA2 and Ca++ uptake into…”
BackgroundIntegrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γ
Perino, A., Ghigo, A., Ferrero, E., Morello, F., Santulli, G., Baillie, G. S., Damilano, F., Dunlop, A. J., Pawson, C., Walser, R., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.030 · Cited by 200 · cited 1×
“…PKA, PKB 14-3-3 binding regulates PDE3 activity (Palmer et al, 2007) PI3Kc MAPK, PKB, PKA Inflammation, cardiac contractility (Patrucco et al, 2004; Perino et al, 2011) PI3Kc Epac Angiogenesis, cell adhesion (Wilson et al, 2011) PDE4 Disc1 PDE4D9, ATF4, D1-R Neuronal functions (Soda et al, 2013)…”
BackgroundMutation in PDE8B,a Cyclic AMP–Specific Phosphodiesterase in Adrenal Hyperplasia
Horvath, A., Mericq, V., & Stratakis, C. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0706182 · Cited by 190
Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F. S., & Fusco, F. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013417 · Cited by 184 · cited 1×
“Also, in a transgenic R6/2 mouse model of Huntington’s disease, inhibition of PDE4 or PDE10A alleviated motor and behavioral deficits (DeMarch et al, 2008; Giampa et al, 2010).”
BackgroundAriga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M. P., Jin, S.-L. C., & Conti, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7531 · Cited by 181 · cited 1×
“Many studies, especially those with PDE4 KO mice, have demonstrated that individual PDE4 subtypes play complementary, not redundant, roles in the control of cell functions (Hansen et al, 2000; Jin and Conti, 2002; Ariga et al, 2004; Jin et al, 2006; Peter et al, 2007; Beca et al, 2011).”
BackgroundAlterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B–null mice
Choi, Y. H., Park, S., Hockman, S., Zmuda-Trzebiatowska, E., Svennelid, F., Haluzik, M., Gavrilova, O., Ahmad, F., Pepin, L., Napolitano, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24867 · Cited by 180 · cited 4×
“For example, cell-based studies (Walz et al, 2007), studies with PDE3B KO mice (Choi et al, 2006), and studies in transgenic mice overexpressing PDE3B in pancreatic b-cells (Harndahl et al, 2002) clearly establish a central role for PDE3B in regulation of insulin secretion.”
BackgroundInfluentialSelf-citationRamamurthy, V., Niemi, G. A., Reh, T. A., & Hurley, J. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404197101 · Cited by 180 · cited 1×
“Mutations in AILP1 (the gene encoding aryl hydrocarbon receptorinteracting protein-like 1), a chaperone of PDE6A, allow proteolytic destruction of PDE6A and are associated with Leber congenital amaurosis type 4, a severe form of childhood blindness (Ramamurthy et al, 2004).”
BackgroundCyclic Nucleotide Phosphodiesterases in Health and Disease
(2006) · CRC Press eBooks · doi:10.1201/9781420020847 · Cited by 173
Franciosi, L. G., Diamant, Z., Banner, K. H., Zuiker, R., Morelli, N., Kamerling, I. M. C., de Kam, M. L., Burggraaf, J., Cohen, A. F., Cazzola, M., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70187-5 · Cited by 169 · cited 1×
“These studies suggest that acute administration (inhalation) of RPL554 improves lung function with bronchodilator and anti-inflammatory responses and with lack of gastrointestinal side effects of ‘classical’ PDE4 inhibitors (Page and Spina, 2012; Calzetta et al, 2013; Franciosi et al, 2013).”
BackgroundBolger, G. B., Peden, A. H., Steele, M. R., MacKenzie, C., McEwan, D. G., Wallace, D. A., Huston, E., Baillie, G. S., & Houslay, M. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303269200 · Cited by 168 · cited 1×
“…transport (Lee et al, 2007) PKA,PDE4D, Epac1, VE-Cad VEC permeability and adhesion(Rampersad et al, 2010) PDE4A5, XAP2 Attenuation of PDE activity (Bolger et al, 2003) PDE4B, LTCC Myocyte Ca++ release (Leroy et al, 2011) HSP20, PKA, bAR Myocyte hypertrophy (Sin et al, 2011) PDE4D, SERCA2, PLN…”
BackgroundStangherlin, A., Gesellchen, F., Zoccarato, A., Terrin, A., Fields, L. A., Berrera, M., Surdo, N. C., Craig, M. A., Smith, G., Hamilton, G., et al. (2011) · Circulation Research · doi:10.1161/circresaha.110.230698 · Cited by 165 · cited 2×
“…and diversity of compartmentalized cyclic nucleotide signaling and allows integration and cross talk between cyclic nucleotide signals and other signaling networks and systems (Dodge et al, 2001; Houslay et al, 2007; Dodge-Kafka et al, 2010; Stangherlin et al, 2011; Kritzer et al, 2012).”
BackgroundGlucocorticoid-induced osteoporosis
Saag, K. G. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00064-6 · Cited by 164
Phototransduction: crystal clear
Ridge, K. D., Abdulaev, N. G., Sousa, M., & Palczewski, K. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00172-5 · Cited by 163 · cited 1×
“PDE6 is highly expressed in photoreceptors and pineal gland (Morin et al, 2001; Ridge et al, 2003).”
BackgroundSildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy
Adamo, C. M., Dai, D.-F., Percival, J. M., Minami, E., Willis, M. S., Patrucco, E., Froehner, S. C., & Beavo, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013077107 · Cited by 162 · cited 1×
“Sildenafil has been reported to prevent cardiac dysfunction and cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy (Adamo et al, 2010), and there are ongoing clinical trials designed to test the effectiveness of PDE5 inhibitors in Becker and Duchenne muscular dystrophies, heart…”
BackgroundPhosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF
Pullamsetti, S. S., Banat, G. A., Schmall, A., Szibor, M., Pomagruk, D., Hänze, J., Kołosionek, E., Wilhelm, J., Braun, T. W., Grimminger, F., et al. (2012) · Oncogene · doi:10.1038/onc.2012.136 · Cited by 160
Pandit, J., Forman, M. D., Fennell, K. F., Dillman, K. S., & Menniti, F. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907635106 · Cited by 160 · cited 3×
“GAF domain structures of PDEs 2, 5, 6, 10, and 11 reveal differences in dimerization properties and highlight the structural diversity of GAF domain-containing PDEs (Heikaus et al, 2009; Pandit et al, 2009).”
BackgroundTargeting cancer with phosphodiesterase inhibitors
Savai, R., Pullamsetti, S. S., Banat, G.-A., Weißmann, N., Ghofrani, H. A., Grimminger, F., & SCHERMULY, R. T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903485642 · Cited by 159 · cited 1×
“Inhibition of selected isoforms of PDEs could provide antitumor therapy by regulating the intracellular levels of compartmentalized cAMP and cGMP, and thus inhibit cell growth and migration and/or induce apoptosis in target tumor cells (Table 1) (Savai et al, 2010).”
BackgroundKe, H., & Wang, H. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779941242 · Cited by 159 · cited 2×
“Cocrystallization of PDEinhibitor complexes suggests that the invariant glutamine and a highly conserved phenylalanine (tryptophan in PDE11) are also required for inhibitor binding (Ke and Wang, 2007).”
BackgroundPitari, G. M., Guglielmo, M. D. D., Park, J. Y., Schulz, S., & Waldman, S. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141124698 · Cited by 157 · cited 1×
“Similarly, elevated cGMP levels, via activation of cGMP/PKG signaling, inhibited tumor cell growth and migration (Shailubhai et al, 2000; Pitari et al, 2001; Deguchi et al, 2004).”
BackgroundPhosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases
Page, C. P., & Spina, D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_17 · Cited by 156 · cited 19×
“Conversely, disruptions in these signaling pathways play key roles in the pathogenesis and symptomatic presentations of many clinically relevant disease states, including obesity, diabetes, heart failure, pulmonary hypertension, erectile dysfunction, chronic obstructive pulmonary disease (COPD), arthritis, certain for…”
BackgroundInfluentialHansen, G., Jin, S.-L. C., Umetsu, D. T., & Conti, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6751 · Cited by 154 · cited 1×
“Many studies, especially those with PDE4 KO mice, have demonstrated that individual PDE4 subtypes play complementary, not redundant, roles in the control of cell functions (Hansen et al, 2000; Jin and Conti, 2002; Ariga et al, 2004; Jin et al, 2006; Peter et al, 2007; Beca et al, 2011).”
BackgroundFrancis, S. H., Colbran, J. L., McAllister‐Lucas, L. M., & Corbin, J. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31669-1 · Cited by 154 · cited 1×
“It contains a histidine-rich PDE signature sequence motif [HD(X2)H (X4)N] and two consensus metal-binding domains (HX3HX24-26E), which are common to all PDEs and critical for catalytic function (Francis et al, 1994; Zhang et al, 2002).”
BackgroundPDE4 as a target for cognition enhancement
Richter, W., Menniti, F. S., Zhang, H., & Conti, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.818656 · Cited by 153 · cited 6×
“PDE4 inhibitors, which were initially observed to exhibit antidepressant actions in humans (Wachtel, 1983), improve cognition and long-term memory in healthy rodents as well as rodent models of human genetic diseases (Richter et al, 2013).”
BackgroundInfluentialNagel, D. J., Aizawa, T., Jeon, K., Liu, W., Mohan, A. M., Wei, H., Miano, J. M., Florio, V. A., Gao, P., Korshunov, V. A., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000215576.27615.fd · Cited by 150
Selective PDE inhibitors as novel treatments for respiratory diseases
Page, C. P., & Spina, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.016 · Cited by 149 · cited 1×
“These studies suggest that acute administration (inhalation) of RPL554 improves lung function with bronchodilator and anti-inflammatory responses and with lack of gastrointestinal side effects of ‘classical’ PDE4 inhibitors (Page and Spina, 2012; Calzetta et al, 2013; Franciosi et al, 2013).”
BackgroundLeroy, J., Richter, W., Mika, D., Castro, L. R., Abi‐Gerges, A., Xie, M., Scheitrum, C., Lefebvre, F., Schittl, J., Matéo, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44747 · Cited by 149 · cited 4×
“…AKAP16/AKAP18organized signalosome, PDE4B is tethered to L-type Ca++ channels (LTCC) and colocalized with the LTCC along Ttubules where it seems to be involved in the regulation of cAMP/PKA-induced Ca++ uptake and protection against ventricular arrythmias (Lehnart et al, 2005; Leroy et al, 2011).”
BackgroundInfluentialStefan, E., Wiesner, B., Baillie, G. S., Mollajew, R., Henn, V., Lorenz, D., Furkert, J., Santamaria, K., Nedvetsky, P. I., Hundsrucker, C., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020132 · Cited by 148 · cited 1×
“…(MacKenzie et al, 2011) Disc1 PDE4B, GSK3 Etiology of schizophrenia and depression (Lipina et al, 2012) AKAP18d PKA,PDE4D Water reabsorption (Stefan et al, 2007) Yotiao I(Ks), PDE4D3, PKA, PP1, KCNQ1, AC Cardiac I(Ks) potassium channel and arrhythmia (Terrenoire et al, 2009) AKAP79 PDE4D,…”
BackgroundBolger, G. B., Baillie, G. S., Li, X., Lynch, M. J., Herzyk, P., Mohamed, A., High Mitchell, L., McCahill, A., Hundsrucker, C., Klussmann, E., et al. (2006) · Biochemical Journal · doi:10.1042/bj20060423 · Cited by 147 · cited 1×
“2, PLB Arrhythmia (Ghigo et al, 2012) PI3K PKB, PDE4 Activation of T-cells (Bjorgo et al, 2010) RACK-1, b-arrestin PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1…”
BackgroundHutson, P. H., Finger, E. N., Magliaro, B. C., Smith, S. M., Converso, A., Sanderson, P. E. J., Mullins, D. E., Hyde, L. A., Eschle, B. K., Turnbull, Z., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.009 · Cited by 146
The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3
Terrenoire, C., Houslay, M. D., Baillie, G. S., & Kass, R. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805366200 · Cited by 143 · cited 1×
“…AKAP18d PKA,PDE4D Water reabsorption (Stefan et al, 2007) Yotiao I(Ks), PDE4D3, PKA, PP1, KCNQ1, AC Cardiac I(Ks) potassium channel and arrhythmia (Terrenoire et al, 2009) AKAP79 PDE4D, b-arrestin, b2AR, ERK, PKA b2AR activation of ERK (Lynch et al, 2005) AKAP95, AKAP149, MTG PDE4A, PDE7A,…”
BackgroundCyclic AMP compartments and signaling specificity: Role of cyclic nucleotide phosphodiesterases
Conti, M., Mika, D., & Richter, W. (2013) · The Journal of General Physiology · doi:10.1085/jgp.201311083 · Cited by 142 · cited 2×
“PDEs are not only critical regulators of the amplitude, duration, and termination of intracellular cyclic nucleotide signals, but PDEs also play an important role in this exquisite compartmentalization (Houslay, 2010; Conti et al, 2014; Maurice et al, 2014a).”
BackgroundPDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia
Fatemi, S. H., King, D. P., Reutiman, T. J., Folsom, T. D., Laurence, J. A., Lee, S. S., Fan, Y.-T., Paciga, S. A., Conti, M., & Menniti, F. S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.029 · Cited by 142 · cited 1×
“…polymorphisms (SNPs) have been correlated with ischemic stroke (Gretarsdottir et al, 2003) and with responses to short-acting bronchodilators in pediatric asthma (Labuda et al, 2011), whereas PDE4B SNPs and decreased expression of PDE4B are associated with schizophrenia (Fatemi et al, 2008).”
BackgroundTadalafil for the Treatment of Pulmonary Arterial Hypertension
Oudiz, R. J., Brundage, B. H., Galiè, N., Ghofrani, H. A., Simonneau, G., Botros, F. T., Chan, M., Beardsworth, A., & Barst, R. J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.05.004 · Cited by 142
Phosphodiesterases in neurodegenerative disorders
Bollen, E., & Prickaerts, J. (2012) · IUBMB Life · doi:10.1002/iub.1104 · Cited by 141 · cited 2×
“…tested as therapeutics for cognitive and behavioral deficits in dementia, schizophrenia, and Alzheimer’s disease, as well as in the neurodegenerative Huntington’s disease (Kehler and Nielsen, 2011; Bollen and Prickaerts, 2012; Richter et al, 2013) (cf Clinictrails.gov; and Maurice et al, 2014a).”
BackgroundReed, T. M., Repaske, D. R., Snyder, G. L., Greengard, P., & Vorhees, C. V. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-12-05188.2002 · Cited by 140 · cited 1×
“Targeted inactivation of PDE1B alters locomotion activity and DARPP-32 phosphorylation in response to dopamine agonists and displays impaired spatial learning (Reed et al, 2002).”
BackgroundExome Sequencing Identifies PDE4D Mutations in Acrodysostosis
Lee, H., Graham, J. M., Rimoin, D. L., Lachman, R. S., Krejčı́, P., Tompson, S. W. J., Nelson, S. F., Krakow, D., & Cohn, D. H. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.03.004 · Cited by 136 · cited 1×
“PDE4D mutations have been reported in patients with acrodysostosis (a rare autosomal-dominant condition characterized by facial dysostosis, severe brachydactyly, and short stature) (Lee et al, 2012).”
BackgroundTaira, M., Hockman, S. C., Calvo, J. C., Taira, M., Belfrage, P., & Manganiello, V. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46666-x · Cited by 136 · cited 1×
“…include two domains: NHR1 (amino acids 1–300), which contains a large hydrophobic domain with five to six predicted transmembrane helices, and NHR2 (aa 300–500), with a smaller hydrophobic region of ~50 aa (Taira et al, 1993; Degerman et al, 1997; Hambleton et al, 2005; Conti and Beavo, 2007).”
BackgroundSelf-citationSeybold, J., Thomas, D., Witzenrath, M., Boral, Ş., Hocke, A. C., Bürger, A., Hatzelmann, A., Tenor, H., Schudt, C., Krüll, M., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2729 · Cited by 135
Beca, S., Ahmad, F., Shen, W., Liu, J., Makary, S., Polidovitch, N., Sun, J., Hockman, S., Chung, Y. W., Movsesian, M., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300003 · Cited by 135 · cited 4×
“…et al, 2002) PDE2 SPHKAP PKA/PKG Cardiac adrenergic response (Aye et al, 2012) PDE3A AKAP18 SERCA2, PKA-R, PP2A, PLN SR Ca2+ uptake and myocardial function (Beca et al, 2013) BIG PKA-R ARF function (Puxeddu et al, 2009) 14-3-3 PKC Platelet inhibition (Hunter et al, 2009) PI3Kc PKA, bAR, Cav1.”
BackgroundInfluentialSelf-citationBeneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
DeMarch, Z., Giampà, C., Patassini, S., Bernardi, G., & Fusco, F. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.02.010 · Cited by 135 · cited 1×
“Also, in a transgenic R6/2 mouse model of Huntington’s disease, inhibition of PDE4 or PDE10A alleviated motor and behavioral deficits (DeMarch et al, 2008; Giampa et al, 2010).”
BackgroundRegulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart
Chen, Y., Miller, C. L., & Abe, J. (2007) · Circulation Research · doi:10.1161/01.res.0000258451.44949.d7 · Cited by 135
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Wittmann, M., & Helliwell, P. (2013) · Dermatology and Therapy · doi:10.1007/s13555-013-0023-0 · Cited by 132 · cited 3×
“The PDE4 inhibitor, apremilast (Otezia: Celgene), was recently FDA-approved for the treatment of psoriatic arthritis (Wittmann and Helliwell, 2013; FitzGerald, 2014), and GSK256066 (administered by inhalation) was reported to reduce responses to inhaled allergen is a small asthma trial (Singh et al, 2010).”
BackgroundBeard, M. B., Olsen, A. E., Jones, R. E., Erdogan, S., Houslay, M. D., & Bolger, G. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10349 · Cited by 129 · cited 1×
“Studies suggest that UCR1 and UCR2 form an interacting module that regulates PDE4 dimerization and catalytic activity, and also allow interactions with heterologous regulatory partners (Beard et al, 2000; Richter and Conti, 2002; Francis et al, 2011).”
BackgroundRivet, M., Vandecasteele, G., Hatem, S. N., Verde, I., Benardeau, A. M., Mercadier, J.-J., & Fischmeister, R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119460 · Cited by 129
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
Banner, K. H., & Press, N. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00170.x · Cited by 128 · cited 4×
“…of combinations of PDE4 inhibitors (roflumilast) and inhaled corticosteroids, LABAs such as salmeterol, or anticholinergics such as the muscarinic receptor antagonist tiotropium (approved as combination therapy for COPD) (Banner and Press, 2009; Giembycz and Newton, 2011; Page and Spina, 2011).”
BackgroundInfluentialKerfant, B., Zhao, D., Lorenzen‐Schmidt, I., Wilson, L. S., Cai, S., Chen, S. R. W., Maurice, D. H., & Backx, P. H. (2007) · Circulation Research · doi:10.1161/circresaha.107.156422 · Cited by 128 · cited 1×
“…contractility in rodents, different PDE3 and PDE4 isoforms are associated with AKAPbased signalosomes thought to modulate effects of cAMP on L-type and ryanodine-sensitive Ca2+ channels (RyR2) as well as SERCA2 (Lehnart et al, 2005; Kerfant et al, 2007; Leroy et al, 2011; Beca et al, 2013).”
BackgroundSelf-citationStevens, J., Simpson, E. L., Harnan, S., Squires, H., Meng, Y., Thomas, S., Michaels, J. A., & Stansby, G. P. (2012) · British journal of surgery · doi:10.1002/bjs.8895 · Cited by 127
Peter, D., Jin, S. L. C., Conti, M., Hatzelmann, A., & Zitt, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4820 · Cited by 126
AKAPs: The architectural underpinnings of local cAMP signaling
Kritzer, M. D., Li, J., Dodge‐Kafka, K. L., & Kapiloff, M. S. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.05.002 · Cited by 126 · cited 6×
“In addition, following bAR-agonist stimulation, PDE4D5 preferentially associates with b-arrestin and the complex is recruited to the bAR in the vicinity of plasma membranes (PM), where it is involved in the regulation of bAR signaling and trafficking (Houslay et al, 2007; Kritzer et al, 2012).”
BackgroundInfluentialDeguchi, A., Thompson, W. J., & Weinstein, I. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3740 · Cited by 125 · cited 1×
“Similarly, elevated cGMP levels, via activation of cGMP/PKG signaling, inhibited tumor cell growth and migration (Shailubhai et al, 2000; Pitari et al, 2001; Deguchi et al, 2004).”
BackgroundHambleton, R., Krall, J., Tikishvili, E., Honeggar, M., Ahmad, F., Manganiello, V. C., & Movsesian, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506760200 · Cited by 125 · cited 7×
“Table 2 PDE-containing signalosomes PDE Scaffold/Docking proteins Signaling partners Function PDE1 (Ca2+)calmodulin Sperm function (Lefievre et al, 2002) PDE2 SPHKAP PKA/PKG Cardiac adrenergic response (Aye et al, 2012) PDE3A AKAP18 SERCA2, PKA-R, PP2A, PLN SR Ca2+ uptake and myocardial function (Beca et al, 2013) BIG…”
BackgroundInfluentialSelf-citationAKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade
Smith, F. D., Langeberg, L. K., Cellurale, C., Pawson, T., Morrison, D. K., Davis, R. J., & Scott, J. D. (2010) · Nature Cell Biology · doi:10.1038/ncb2130 · Cited by 123 · cited 1×
“…activation (Asirvatham et al, 2004) PDE8 AKAP-LBC PDE8A, Raf1, PKA, AKAP-Lbc, MEK, ERK PDE8A binds Raf1 and exerts inhibitory effect on Raf1 and ERK signaling (Smith et al, 2010; Brown et al, 2013) Oral Diseases 6 Variants lacking both UCR1 and UCR2 are catalytically inactive (Houslay et al, 2005).”
BackgroundPhosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors
Libé, R., Fratticci, A., Coste, J., Tissier, F., Horvath, A., Ragazzon, B., Rene-Corail, F., Groussin, L., Bertagna, X., Raffin-Sanson, M. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0106 · Cited by 123 · cited 1×
“Inactivating PDE11A gene mutations are also associated with the development of adrenal hyperplasia and Cushing syndrome (Libe et al, 2008), and with Carney complex (CNC).”
BackgroundSignal transducing membrane complexes of photoreceptor outer segments
Wensel, T. G. (2008) · Vision Research · doi:10.1016/j.visres.2008.03.010 · Cited by 123
Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3)
Shakur, Y., Takeda, K., Kenan, Y., Yu, Z., Rena, G., Brandt, D., Houslay, M. D., Degerman, E., Ferrans, V. J., & Manganiello, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001734200 · Cited by 122 · cited 1×
“…of PDE3A and PDE3B and immunofluorescence localization of PDE3B in 3T3-L1 adipocytes suggested that structural determinants responsible for membrane association are localized in NHR1 domain while NHR2 seemed to be important for efficient membrane association and targeting (Shakur et al, 2000).”
BackgroundSelf-citationGroß-Langenhoff, M., Hofbauer, K., Weber, J. H., Schultz, A. C. F., & Schultz, J. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511468200 · Cited by 122 · cited 1×
“(Wu et al, 2004; Gross-Langenhoff et al, 2006; Heikaus et al, 2008).”
Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons
Cygnar, K. D., & Zhao, H. (2009) · Nature Neuroscience · doi:10.1038/nn.2289 · Cited by 121 · cited 1×
“In PDE1C knockout mice, olfactory sensory neurons (OSNs) show reduced sensitivity and attenuated adaptation to repeated stimulation (Cygnar and Zhao, 2009).”
BackgroundPDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Kehler, J., & Nielsen, J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049624 · Cited by 121 · cited 2×
“…tested as therapeutics for cognitive and behavioral deficits in dementia, schizophrenia, and Alzheimer’s disease, as well as in the neurodegenerative Huntington’s disease (Kehler and Nielsen, 2011; Bollen and Prickaerts, 2012; Richter et al, 2013) (cf Clinictrails.gov; and Maurice et al, 2014a).”
BackgroundMiyazawa, T., Ogawa, Y., Chusho, H., Yasoda, A., Tamura, N., Komatsu, Y., Pfeifer, A., Hofmann, F. B., & Nakao, K. (2002) · Endocrinology · doi:10.1210/en.2002-220307 · Cited by 121 · cited 1×
“Prkg2 knockout mice, deficient in type II cGMP-dependent protein kinase (PKG), exhibit a dwarfism phenotype, with impaired endochondral ossification (Miyazawa et al, 2002).”
BackgroundHagiwara, H., Inoue, A., Yamaguchi, A., Yokose, S., Furuya, M., Tanaka, S., & Hirose, S. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.270.5.c1311 · Cited by 120 · cited 1×
“…factor alpha1 (Cbfa1)-regulated expression of osteoblast-specific genes such as osteopontin, collagen type I, osteocalcin, and sialoproteins (Rodan and Noda, 1991). cGMP has also been shown to regulate differentiation of osteoblasts (Hagiwara et al, 1996; Broderick et al, 2007; Wimalawansa, 2008).”
BackgroundKatakami, N., Kim, Y.-S., Kawamori, R., & Yamasaki, Y. (2010) · Circulation · doi:10.1161/circulationaha.109.892414 · Cited by 120 · cited 1×
“…has been reported to attenuate postangioplasty restenosis and reduce the progression of atherosclerosis in diabetic patients (Tamhane et al, 2009; Katakami et al, 2010), most likely due to its inhibitory effects on vascular smooth muscle proliferation and vascular wall inflammation (Liu et al,…”
BackgroundMurray, F., Patel, H. H., Suda, R. Y. S., Zhang, S., Thistlethwaite, P. A., Yuan, J. X. ‐., & Insel, P. A. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00190.2006 · Cited by 120 · cited 1×
“Similarly, knockdown of PDE1C in VSMC from pulmonary arteries from patients with pulmonary hypertension increased cAMP content and inhibited cell growth (Murray et al, 2007).”
BackgroundCyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies
Lerner, A., & Epstein, P. M. (2005) · Biochemical Journal · doi:10.1042/bj20051368 · Cited by 119 · cited 2×
“As there is a considerable cross talk between glucocorticoid and cAMP signaling pathways (Tiwari et al, 2005; Lerner and Epstein, 2006), PDE inhibitors, by acting to both promote bone formation and inhibit bone resorption, might fill a critical need as therapeutics for glucocorticoidinduced osteoporosis.”
BackgroundLibé, R., Horvath, A., Vezzosi, D., Fratticci, A., Coste, J., Perlemoine, K., Ragazzon, B., Guillaud-Bataille, M., Groussin, L., Clauser, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1704 · Cited by 116 · cited 1×
“CNC is caused by germline mutations in the alpha regulatory subunit of PKA (PRKARIA) and is associated with endocrine tumors, including nodular adrenal hyperplasia and adrenal and testicular tumors (Levy et al, 2011; Libe et al, 2011).”
BackgroundCyclic Nucleotide Binding GAF Domains from Phosphodiesterases: Structural and Mechanistic Insights
Heikaus, C. C., Pandit, J., & Klevit, R. E. (2009) · Structure · doi:10.1016/j.str.2009.07.019 · Cited by 112 · cited 1×
“GAF domain structures of PDEs 2, 5, 6, 10, and 11 reveal differences in dimerization properties and highlight the structural diversity of GAF domain-containing PDEs (Heikaus et al, 2009; Pandit et al, 2009).”
BackgroundVEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors
Favot, L., Keravis, T. M., Holl, V., Bec, A. L., & Lugnier, C. (2003) · Thrombosis and Haemostasis · doi:10.1160/th03-02-0084 · Cited by 110
Richter, W., & Conti, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203585200 · Cited by 110 · cited 1×
“Studies suggest that UCR1 and UCR2 form an interacting module that regulates PDE4 dimerization and catalytic activity, and also allow interactions with heterologous regulatory partners (Beard et al, 2000; Richter and Conti, 2002; Francis et al, 2011).”
BackgroundBeca, S., Helli, P. B., Simpson, J. A., Zhao, D., Farman, G. P., Jones, P. P., Tian, X., Wilson, L. S., Ahmad, F., Chen, S. R. W., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.250464 · Cited by 110 · cited 3×
“2, PLB Arrhythmia (Ghigo et al, 2012) PI3K PKB, PDE4 Activation of T-cells (Bjorgo et al, 2010) RACK-1, b-arrestin PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal devel…”
BackgroundSelf-citationStructural basis for the design of selective phosphodiesterase 4B inhibitors
Fox, D. N. A., Burgin, A. B., & Gurney, M. E. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.12.003 · Cited by 109 · cited 2×
“Further studies have shown that a single polymorphism in the CR3 helix (Leu 674 in PDE4B1 verses Gln594 in PDE4D), which interacts with a 2-arylpyrimidine PDE4 inhibitor (A-33), is responsible for the70- to 80-fold subtype selectivity of A-33 for PDE4B over PDE4D (Fox et al, 2014).”
BackgroundRampersad, S. N., Ovens, J. D., Huston, E., Umana, M. B., Wilson, L. S., Netherton, S. J., Lynch, M. J., Baillie, G. S., Houslay, M. D., & Maurice, D. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.140004 · Cited by 108 · cited 1×
“…(Collins et al, 2008) SHANK PDE4D, CFTR, PKA Membrane ion transport (Lee et al, 2007) PKA,PDE4D, Epac1, VE-Cad VEC permeability and adhesion(Rampersad et al, 2010) PDE4A5, XAP2 Attenuation of PDE activity (Bolger et al, 2003) PDE4B, LTCC Myocyte Ca++ release (Leroy et al, 2011) HSP20, PKA,…”
BackgroundSelf-citationHashimoto, Y., Sharma, R. K., & Soderling, T. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81703-3 · Cited by 108 · cited 1×
“Phosphorylation of PDE1 isozymes by PKA or Ca2+–CaM protein kinase results in a decrease in the affinity of isozymes for Ca2+– CaM (Hashimoto et al, 1989).”
MethodWouters, E. F. M., Bredenbröker, D., Teichmann, P., Brose, M., Rabe, K. F., Fabbri, L. M., & Göke, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2886 · Cited by 107 · cited 1×
“In fact, during clinical trials with roflumilast, subjects reported weight loss, and in a small number of newly diagnosed patients with type 2 diabetes, roflumilast was reported to reduce blood glucose and glycated hemoglobin (Rabe, 2011; Wouters et al, 2012).”
BackgroundShort Term Feedback Regulation of cAMP in FRTL-5 Thyroid Cells
Oki, N., Takahashi, S.-I., Hidaka, H., & Conti, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10831 · Cited by 107 · cited 1×
“Thus, UCR1 and UCR2 play a key role in defining the functional response of PDE4D long and short isoenzymes to PKA and ERK phosphorylation (MacKenzie et al, 2000; Oki et al, 2000).”
BackgroundTsai, L.-C. L., Shimizu‐Albergine, M., & Beavo, J. A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.069104 · Cited by 107 · cited 2×
“PDE8B KO mice exhibit increased expression of several steroidogenic proteins and increased urinary corticosterone levels (Tsai et al, 2011).”
BackgroundLee, J. H., Richter, W., Namkung, W., Kim, K. H., Kim, E., Conti, M., & Lee, M. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610857200 · Cited by 107 · cited 1×
“…EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal development (Collins et al, 2008) SHANK PDE4D, CFTR, PKA Membrane ion transport (Lee et al, 2007) PKA,PDE4D, Epac1, VE-Cad VEC permeability and adhesion(Rampersad et al, 2010) PDE4A5, XAP2 Attenuation of PDE activity (Bolger et…”
BackgroundTinsley, H. N., Gary, B. D., Keeton, A. B., Lü, W., Li, Y., & Piazza, G. A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0095 · Cited by 107 · cited 1×
“…cGMP, was recently reported to be increased in human breast cancer cell lines (Dong et al, 2013), in other human breast cancer cells, inhibition of PDE5, another cGMP-specific PDE, by siRNA-induced PDE5 knockdown or inhibition with the drug, sulidac, promoted apoptosis (Tinsley et al, 2011).”
BackgroundMillar, J. K., Mackie, S., Clapcote, S. J., Murdoch, H., Pickard, B. S., Christie, S., Muir, W. J., Blackwood, D. H., Roder, J. C., Houslay, M. D., et al. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.140210 · Cited by 106 · cited 1×
“In addition, DISC1 (disrupted in schizophrenia homolog 1), a known risk factor for schizophrenia, and PDE4B interact physically in cells to influence the catalytic activity of PDE4B (Table 2) (Clapcote et al, 2007; Millar et al, 2007).”
BackgroundKinoshita, T., Kobayashi, S., Ebara, S., Yoshimura, Y., Horiuchi, H., Tsutsumimoto, T., Wakabayashi, S., & Takaoka, K. (2000) · Bone · doi:10.1016/s8756-3282(00)00395-1 · Cited by 105 · cited 1×
“A number of studies suggest that PDE inhibitors promote bone formation via stimulation of osteoblast differentia- tion/formation (Kinoshita et al, 2000; Wakabayashi et al, 2002; Tokuhara et al, 2010) and/or inhibition of bone resorption (Park and Yim, 2007; Yao et al, 2007; Noh et al, 2009), and…”
BackgroundGhigo, A., Perino, A., Mehel, H., Zahradníková, A., Morello, F., Leroy, J., Nikolaev, V. O., Damilano, F., Cimino, J. J., Luca, E. D., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.114074 · Cited by 104 · cited 4×
“2, PLB Arrhythmia (Ghigo et al, 2012) PI3K PKB, PDE4 Activation of T-cells (Bjorgo et al, 2010) RACK-1, b-arrestin PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal devel…”
BackgroundInfluentialSin, Y. Y., Edwards, H. V., Li, X., Day, J. P., Christian, F., Dunlop, A. J., Adams, D. R., Zaccolo, M., Houslay, M. D., & Baillie, G. S. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.02.006 · Cited by 103 · cited 2×
“…XAP2 Attenuation of PDE activity (Bolger et al, 2003) PDE4B, LTCC Myocyte Ca++ release (Leroy et al, 2011) HSP20, PKA, bAR Myocyte hypertrophy (Sin et al, 2011) PDE4D, SERCA2, PLN Cardiac Contractility (Beca et al, 2011) PDE5 IP(3)R1, PKG, IRAG Platelet function (Wilson et al, 2008) PDE6…”
BackgroundCalzetta, L., Page, C. P., Spina, D., Cazzola, M., Rogliani, P., Facciolo, F., & Matera, M. G. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204644 · Cited by 102 · cited 1×
“These studies suggest that acute administration (inhalation) of RPL554 improves lung function with bronchodilator and anti-inflammatory responses and with lack of gastrointestinal side effects of ‘classical’ PDE4 inhibitors (Page and Spina, 2012; Calzetta et al, 2013; Franciosi et al, 2013).”
BackgroundFan, G., Yuan, Q., Song, G., Wang, Y., Chen, G., Qian, J., Zhou, X., Lee, Y. J., Ashraf, M., & Kranias, E. G. (2006) · Circulation Research · doi:10.1161/01.res.0000251074.19348.af · Cited by 102 · cited 2×
“Exposure of cultured cardiomyocytes to a cell-permeable peptide, designed to disrupt interactions between the PDE4 catalytic domain and HSP60, disrupted the complex, increased PKA-induced phosphorylation of HSP60, and attenuated the hypertrophic response (Fan et al, 2006; Sin et al, 2011).”
BackgroundDodge-Kafka, K. L., Bauman, A., Mayer, N., Henson, E., Heredia, L., Ahn, J., McAvoy, T., Nairn, A. C., & Kapiloff, M. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.034868 · Cited by 97 · cited 7×
“…and diversity of compartmentalized cyclic nucleotide signaling and allows integration and cross talk between cyclic nucleotide signals and other signaling networks and systems (Dodge et al, 2001; Houslay et al, 2007; Dodge-Kafka et al, 2010; Stangherlin et al, 2011; Kritzer et al, 2012).”
BackgroundInfluentialRothenbuhler, A., Horvath, A., Libé, R., Faucz, F. R., Fratticci, A., Raffin Sanson, M. L., Vezzosi, D., Azevedo, M., Levy, I., Almeida, M. Q., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04366.x · Cited by 96 · cited 1×
“Mutations in human PDE8B, however, are associated with development of micronodular adrenal hyperplasia, adrenocortical tumors, and clinical signs of Cushing disease (Rothenbuhler et al, 2012).”
BackgroundSano, H., Nagai, Y., Miyakawa, T., Shigemoto, R., & Yokoi, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05152.x · Cited by 95 · cited 1×
“In rodent model systems, PDE10A KO mice exhibited increased social interactions, suggesting that cAMP signaling in striatal medium spiny neurons might be involved in regulating social behavior (Sano et al, 2008).”
BackgroundVinpocetine as a potent antiinflammatory agent
Medina, A. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005138107 · Cited by 93
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Almeida, M. Q., & Stratakis, C. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.11.018 · Cited by 92 · cited 1×
“On the other hand, although PDE inhibitors can inhibit growth of certain tumors, cAMP can also promote hyperplastic changes and growth of tumors (Almeida and Stratakis, 2011).”
BackgroundIdentification of cisplatin‐resistance related genes in head and neck squamous cell carcinoma
Yamano, Y., Uzawa, K., Saito, K., Nakashima, D., Kasamatsu, A., Koike, H., Kouzu, Y., Shinozuka, K., Nakatani, K., Negoro, K., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24704 · Cited by 91 · cited 2×
“…cells, exhibited increased expression of PDE3B compared with parental cell lines (Yamano et al, 2010), and, as assessed by PDE3B immunohistochemical staining, PDE3B expression levels were significantly higher in the tumors unresponsive to cisplatin than in responsive tumors (Yamano et al, 2010).”
BackgroundModulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A
Vasta, V., Shimizu-Albergine, M., & Beavo, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609483103 · Cited by 91 · cited 1×
“PDE8 regulates cAMP-mediated steroidogenesis in adrenocortical tissues and Leydig testicular cells, and plays an important role in regulating the sensitivity to luteinizing hormone for testosterone production (Vasta et al, 2006).”
BackgroundAzzouni, F. S., & Abusamra, K. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02382.x · Cited by 91 · cited 3×
“Because chronic elevations of cGMP in photoreceptors lead to cell death and progressive retinal degeneration (Davis et al, 2008), certain PDE5 inhibitors (e.g., sildenafil and vardenafil), which can inhibit PDE6, are contraindicated in patients with retinal degeneration (Azzouni and Abu, 2011).”
BackgroundSynergistic interactions between PDE4B and GSK-3: DISC1 mutant mice
Lipina, T. V., Wang, M., Liu, F., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.020 · Cited by 90 · cited 1×
“…MK2, PKA and AIP Immune, inflammatory, and stress responses (MacKenzie et al, 2011) Disc1 PDE4B, GSK3 Etiology of schizophrenia and depression (Lipina et al, 2012) AKAP18d PKA,PDE4D Water reabsorption (Stefan et al, 2007) Yotiao I(Ks), PDE4D3, PKA, PP1, KCNQ1, AC Cardiac I(Ks) potassium…”
BackgroundThe inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
Singh, D., Pétavy, F., MacDonald, A. J., Lazaar, A. L., & O'Connor, B. J. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-26 · Cited by 90 · cited 1×
“…inhibitor, apremilast (Otezia: Celgene), was recently FDA-approved for the treatment of psoriatic arthritis (Wittmann and Helliwell, 2013; FitzGerald, 2014), and GSK256066 (administered by inhalation) was reported to reduce responses to inhaled allergen is a small asthma trial (Singh et al, 2010).”
BackgroundHärndahl, L., Jing, X.-J., Ivarsson, R., Degerman, E., Ahrén, B., Manganiello, V. C., Renström, E., & Holst, L. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205401200 · Cited by 89 · cited 1×
“For example, cell-based studies (Walz et al, 2007), studies with PDE3B KO mice (Choi et al, 2006), and studies in transgenic mice overexpressing PDE3B in pancreatic b-cells (Harndahl et al, 2002) clearly establish a central role for PDE3B in regulation of insulin secretion.”
BackgroundSelf-citationChellaiah, M. A., Biswas, R. S., Rittling, S. R., Denhardt, D. T., & Hruska, K. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211074200 · Cited by 87 · cited 2×
“In osteoclasts, Rho-A, which is critical for osteoclast motility and function, can be directly phosphorylated and inactivated by PKA (Chellaiah et al, 2000, 2003; Nakamura et al, 2007).”
BackgroundHorvath, A., Korde, L. A., Greene, M. H., Libé, R., Osório, P. D. S., Faucz, F. R., Raffin‐Sanson, M. L., Tsang, K. M., Drori-Herishanu, L., Patronas, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0884 · Cited by 87 · cited 1×
“PDE11A mutations may also play a role in susceptibility to prostate cancer (Faucz et al, 2011) and testicular germ cell tumors (TGCT) (Horvath et al, 2009).”
BackgroundReorganized PKA-AKAP associations in the failing human heart
Aye, T., Soni, S., van Veen, T. A. B., van der Heyden, M. A. G., Cappadona, S., Varró, A., de Weger, R. A., de Jonge, N., Vos, M. A., Heck, A. J. R., et al. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.06.003 · Cited by 87 · cited 1×
“…proteins Signaling partners Function PDE1 (Ca2+)calmodulin Sperm function (Lefievre et al, 2002) PDE2 SPHKAP PKA/PKG Cardiac adrenergic response (Aye et al, 2012) PDE3A AKAP18 SERCA2, PKA-R, PP2A, PLN SR Ca2+ uptake and myocardial function (Beca et al, 2013) BIG PKA-R ARF function (Puxeddu et…”
BackgroundUpdate in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85 · cited 1×
“Currently, Forteo (N-terminal PTH peptide, 1-34 amino acid) is FDA-approved for anabolic treatment of osteoporosis (Hodsman et al, 2005; Canalis, 2010).”
BackgroundHunter, R. W., MacKintosh, C., & Hers, I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807536200 · Cited by 84 · cited 2×
“…et al, 2002) PDE2 SPHKAP PKA/PKG Cardiac adrenergic response (Aye et al, 2012) PDE3A AKAP18 SERCA2, PKA-R, PP2A, PLN SR Ca2+ uptake and myocardial function (Beca et al, 2013) BIG PKA-R ARF function (Puxeddu et al, 2009) 14-3-3 PKC Platelet inhibition (Hunter et al, 2009) PI3Kc PKA, bAR, Cav1.”
BackgroundElbatarny, H. S., & Maurice, D. H. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00125.2005 · Cited by 83 · cited 1×
“In platelets, PDE3A is constitutively associated with leptin receptor and modulates effects of leptin on platelet activation (Elbatarny and Maurice, 2005).”
BackgroundSelf-citationRegulation of Osteoclast Formation and Function*
Duong, L. T., & Rodan, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010063225902 · Cited by 83 · cited 1×
“Maintenance of normal bone mass depends on the balance between osteoblast bone formation and osteoclast bone destruction (Duong and Rodan, 2001; Boyle et al, 2003).”
BackgroundKinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity
Wang, H., Yan, Z., Yang, S., Cai, J., Robinson, H. H., & Ke, H. (2008) · Biochemistry · doi:10.1021/bi801487x · Cited by 82 · cited 1×
“Analyses of the crystal structures of the catalytic domains of different PDE families (PDEs 1–5 and 7–10) indicate that core catalytic domains exhibit a uniform conformation, with primary differences at their NH2 or COOH terminal ends (Ke and Wang, 2007; Liu et al, 2008; Wang et al, 2008).”
BackgroundYano, M., Kohno, M., Ohkusa, T., Mochizuki, M., Yamada, J., Kohno, M., Hisaoka, T., Ono, K., Tanigawa, T., Kobayashi, S., et al. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.4.h1898 · Cited by 80
Zhang, R., Maratos-Flier, E., & Flier, J. S. (2009) · Endocrinology · doi:10.1210/en.2009-0108 · Cited by 79 · cited 1×
“Compared with their wild-type (WT) counterparts, PDE3B KO mice and PDE4B KO mice were leaner, with lower fat pad weights and smaller adipocytes, and with reduced inflammation in white adipose tissue (WAT) (Choi et al, 2006; Zhang et al, 2009).”
BackgroundEmerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Kukreja, R. C., Salloum, F. N., Das, A., Koka, S., Ockaili, R. A., & Xi, L. (2011) · PubMed · Cited by 79
Begum, N., Hockman, S., & Manganiello, V. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214155 · Cited by 78 · cited 4×
“These knockdown studies suggested that targeting PDE3A and/or PDE1C might reduce the pathological vascular remodeling observed in poststenting and postangioplasty restenosis, atherosclerosis, pulmonary hypertension, and other cardiovascular disorders (Begum et al, 2011; Chan and Yan, 2011).”
BackgroundInfluentialSelf-citationGenomic and functional characterizations of phosphodiesterase subtype 4D in human cancers
Lin, D., Xu, L., Ding, L., Sharma, A., Liu, L.-Z., Yang, H. H., Tan, P. B. O., Vadgama, J. V., Karlan, B. Y., Lester, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218206110 · Cited by 78 · cited 1×
“Targeting of endogenous PDE4D with shRNAs or a specific PDE4 inhibitor caused apoptosis and growth inhibition in multiple types of cancer cells, but not normal cells, and re-expression of PDE4D increased tumor cell growth (Lin et al, 2013).”
BackgroundPenmatsa, H., Zhang, W., Yarlagadda, S., Li, C., Conoley, V. G., Yue, J., Bahouth, S. W., Buddington, R. K., Zhang, G., Nelson, D. J., et al. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-08-0655 · Cited by 76 · cited 1×
“2, PLB Arrhythmia (Ghigo et al, 2012) PKAc, Cdc25C, PP2A Meiosis and female fertility (Shen et al, 2010) CFTR Submucosal gland secretion (Penmatsa et al, 2010) PDE3B IRS,14-3-3 PI3K, HSP90, PKB Insulin-induced signaling complex, cAMP pools, and lipolysis (Ahmad et al, 2007) 14-3-3, Cav-1 PKA-R,…”
BackgroundSelf-citationZmuda‐Trzebiatowska, E., Oknianska, A., Manganiello, V. C., & Degerman, E. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.05.007 · Cited by 75 · cited 1×
“…signaling, phosphorylation of hormone-sensitive lipase (HSL), and lipolysis; this compartmentalization most likely explains the observed inhibition of insulin’s antilipolytic effects by PDE3 inhibitors, but not by PDE4 inhibitors (Elks and Manganiello, 1985; Zmuda-Trzebiatowska et al, 2006).”
BackgroundSelf-citationTamhane, U. U., Meier, P., Chetcuti, S. J., Chen, K., Rha, S., Grossman, P. M., & Gurm, H. S. (2009) · EuroIntervention · doi:10.4244/v5i3a60 · Cited by 75 · cited 1×
“…inhibitors, cilostazol has been reported to attenuate postangioplasty restenosis and reduce the progression of atherosclerosis in diabetic patients (Tamhane et al, 2009; Katakami et al, 2010), most likely due to its inhibitory effects on vascular smooth muscle proliferation and vascular wall…”
BackgroundLefièvre, L., de Lamirande, E., & Gagnon, C. (2002) · Biology of Reproduction · doi:10.1095/biolreprod67.2.423 · Cited by 74 · cited 1×
“Table 2 PDE-containing signalosomes PDE Scaffold/Docking proteins Signaling partners Function PDE1 (Ca2+)calmodulin Sperm function (Lefievre et al, 2002) PDE2 SPHKAP PKA/PKG Cardiac adrenergic response (Aye et al, 2012) PDE3A AKAP18 SERCA2, PKA-R, PP2A, PLN SR Ca2+ uptake and myocardial function…”
BackgroundDavis, R. J., Tosi, J., Janisch, K. M., Kasanuki, J. M., Wang, N., Kong, J., Tsui, I. K., Cilluffo, M. C., Woodruff, M. L., Fain, G., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1422 · Cited by 72 · cited 2×
“Because chronic elevations of cGMP in photoreceptors lead to cell death and progressive retinal degeneration (Davis et al, 2008), certain PDE5 inhibitors (e.g., sildenafil and vardenafil), which can inhibit PDE6, are contraindicated in patients with retinal degeneration (Azzouni and Abu, 2011).”
BackgroundPhosphorylation of PDE3B by Phosphatidylinositol 3-Kinase Associated with the Insulin Receptor
Rondinone, C. M., Carvalho, E., Landström, T. R., Manganiello, V. C., Degerman, E., & Smith, U. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10093 · Cited by 72 · cited 24×
“PDE3-specific inhibitors (cilostamide and trequinsin) did not inhibit the proliferation of human oral malignant melanoma HMG cells, and in human oral osteosarcoma HOSM-1 cells, neither PDE3A nor PDE3B mRNAs were expressed (Murata et al, 2002).”
InfluentialSelf-citationDISC1–ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1
Soda, T., Frank, C. L., Ishizuka, K., Baccarella, A., Park, Y.-U., Flood, Z., Park, S. K., Sawa, A., & Tsai, L.-H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.38 · Cited by 72 · cited 1×
“…et al, 2004; Perino et al, 2011) PI3Kc Epac Angiogenesis, cell adhesion (Wilson et al, 2011) PDE4 Disc1 PDE4D9, ATF4, D1-R Neuronal functions (Soda et al, 2013) Disc1 PDE4A5, MK2, PKA and AIP Immune, inflammatory, and stress responses (MacKenzie et al, 2011) Disc1 PDE4B, GSK3 Etiology of…”
Structural basis for the catalytic mechanism of human phosphodiesterase 9
Liu, S., Mansour, M. N., Dillman, K. S., Perez, J. R., Danley, D. E., Aeed, P. A., Simons, S. P., LeMotte, P. K., & Menniti, F. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708850105 · Cited by 72 · cited 1×
“Analyses of the crystal structures of the catalytic domains of different PDE families (PDEs 1–5 and 7–10) indicate that core catalytic domains exhibit a uniform conformation, with primary differences at their NH2 or COOH terminal ends (Ke and Wang, 2007; Liu et al, 2008; Wang et al, 2008).”
BackgroundLevy, I., Horvath, A., Azevedo, M. F., de Alexandre, R. B., & Stratakis, C. A. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.003 · Cited by 72 · cited 1×
“CNC is caused by germline mutations in the alpha regulatory subunit of PKA (PRKARIA) and is associated with endocrine tumors, including nodular adrenal hyperplasia and adrenal and testicular tumors (Levy et al, 2011; Libe et al, 2011).”
BackgroundWilson, L. S., Elbatarny, H. S., Crawley, S. W., Bennett, B. M., & Maurice, D. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804738105 · Cited by 72 · cited 2×
“In human platelets, PDE5, PKG1B, and inositol-1,4,5-triphosphate receptor type-1 (IP3(3)R1) are integral components of a signalosome that regulates effects of cGMP on IP(3)R1-mediated Ca2+ release (Wilson et al, 2008).”
BackgroundSelf-citationDipyridamole, an Underestimated Vascular Protective Drug
Schaper, W. K. A. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-4659-6 · Cited by 72 · cited 1×
“It is used to prevent postsurgical thromboembolism and stroke, and it can be used for myocardial stress tests (Schaper, 2005).”
BackgroundPhosphodiesterase inhibition in heart failure
Movsesian, M. A., Stehlik, J., Vandeput, F., & Bristow, M. R. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9130-x · Cited by 70
The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis
Tsai, L.-C. L., & Beavo, J. A. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.003 · Cited by 67 · cited 1×
“Such PDE8B mutations may not directly cause adrenal hyperplasia, however, because PDE8B KO mice do not develop adrenal tumors (Tsai and Beavo, 2011).”
BackgroundMacKenzie, K. F., Wallace, D. A., Hill, E. V., Anthony, D. F., Henderson, D. J. P., Houslay, D. M., Arthur, J. S. C., Baillie, G. S., & Houslay, M. D. (2011) · Biochemical Journal · doi:10.1042/bj20101184 · Cited by 65 · cited 1×
“…2011) PDE4 Disc1 PDE4D9, ATF4, D1-R Neuronal functions (Soda et al, 2013) Disc1 PDE4A5, MK2, PKA and AIP Immune, inflammatory, and stress responses (MacKenzie et al, 2011) Disc1 PDE4B, GSK3 Etiology of schizophrenia and depression (Lipina et al, 2012) AKAP18d PKA,PDE4D Water reabsorption (Stefan…”
BackgroundBjørgo, E., Solheim, S. A., Abrahamsen, H., Baillie, G. S., Brown, K. M., Berge, T., Okkenhaug, K., Houslay, M. D., & Taskén, K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00696-09 · Cited by 65 · cited 4×
“2, PLB Arrhythmia (Ghigo et al, 2012) PI3K PKB, PDE4 Activation of T-cells (Bjorgo et al, 2010) RACK-1, b-arrestin PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal devel…”
BackgroundInfluentialMeng, F., Hou, J., Shao, Y., Wu, P., Huang, M., Zhu, X., Cai, Y., Li, Z., Xu, J., Liu, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301189c · Cited by 64 · cited 1×
“The structure-based design approach was recently used to develop potent and family-selective PDE4 (Card et al, 2005; Burgin et al, 2010), PDE9A (Claffey et al, 2012; Meng et al, 2012), and PDE10A (Malamas et al, 2011; Ho et al, 2012) inhibitors.”
MethodPhosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Schmidt, C. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411009 · Cited by 64 · cited 2×
“PDE4 and PDE10 inhibitors, because of their beneficial effects in preclinical models of various neuropsychiatric disorders, are being studied as potential cognition- and memory-enhancing and neuroprotective agents (Schmidt, 2010; Blokland et al, 2012).”
BackgroundMarko, D., Romanakis, K., Zankl, H., Fürstenberger, G., Steinbauer, B., & Eisenbrand, G. (1998) · Cell Biochemistry and Biophysics · doi:10.1007/bf02737806 · Cited by 64 · cited 1×
“For example, in chronic lymphocytic leukemia (CLL) and some malignant carcinoma cells, cAMP levels were significantly decreased due to overexpression of PDE7 (Zhang et al, 2008a) or PDE4 (Marko et al, 1998), respectively.”
BackgroundShakur, Y., Fong, M., Hensley, J., Cone, J. L., Movsesian, M. A., Kambayashi, J., Yoshitake, M., & Liu, Y. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1022186402442 · Cited by 64 · cited 1×
“This improved safety profile of cilostazol may be related to its inhibition of adenosine uptake in the myocardium (by mechanisms independent of inhibition of PDE3) (Shakur et al, 2002; Kambayashi and Liu, 2007).”
BackgroundInvolvement of Phosphodiesterase Isozymes in Osteoblastic Differentiation
Wakabayashi, S., Tsutsumimoto, T., Kawasaki, S., Kinoshita, T., Horiuchi, H., & Takaoka, K. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.2.249 · Cited by 63 · cited 2×
“…number of studies suggest that PDE inhibitors promote bone formation via stimulation of osteoblast differentia- tion/formation (Kinoshita et al, 2000; Wakabayashi et al, 2002; Tokuhara et al, 2010) and/or inhibition of bone resorption (Park and Yim, 2007; Yao et al, 2007; Noh et al, 2009), and…”
BackgroundLee, L. C. Y., Maurice, D. H., & Baillie, G. S. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.216 · Cited by 63 · cited 3×
“These and other studies provide proof of principle regarding use of signalosome disruptors to target individual PDEs and modulate compartmentalized cAMP signaling pathways and biological effects (Keravis and Lugnier, 2012; Lee et al, 2013a; Maurice et al, 2014a).”
BackgroundSelf-citationChaudhary, L. R., & Avioli, L. V. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006807221545 · Cited by 62 · cited 4×
“…or cAMP-generating agents such as PTH and forskolin inhibit ERK2 activation by bFGF and PDGF-BB and thus inhibit osteoblast proliferation through attenuation of MAP kinase pathways and through effects on BMP signaling pathways and on Cbfa1 (Rodan and Noda, 1991; Chaudhary and Avioli, 1998).”
BackgroundInfluentialANTILIPOLYTIC ACTION OF INSULIN: ROLE OF cAMP PHOSPHODIESTERASE ACTIVATION
ELKS, M. L., & MANGANIELLO, V. C. (1985) · Endocrinology · doi:10.1210/endo-116-5-2119 · Cited by 62 · cited 4×
“In adipocytes, spatial segregation of PDE3B-containing signalosomes and the lipolytic machinery allows activated PDE3B to selectively mediate the inhibitory effects of insulin on cAMP/PKA signaling, phosphorylation of hormone-sensitive lipase (HSL), and lipolysis; this compartmentalization most likely explains the obs…”
BackgroundInfluentialSelf-citation
Cited by
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Metadata
- Authors
- Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V
- Venue
- Oral Diseases
- Publisher
- Wiley
- Published
- 2014-09-12
- Volume
- 21
- Issue
- 1
- Pages
- e25-50
- ISSN
- 1354-523X (ISSN-L)
- 1601-0825
- OpenAlex
- W2049374415
- Cited by
- 184
- References
- 261
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.